Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients

Calcified Tissue International

Volumn 61, Issue 5, 1997, Pages 382-385

  Gonnelli, S ^a   Rottoli, P ^b   Cepollaro, C ^b   Pondrelli, C ^b   Cappiello, V ^b   Vagliasindi, M ^b   Gennari, C ^b  

^a Patologia Speciale Medica   (Italy)

^b NONE

Author keywords

Alendronate; Bone mass; Bone turnover; Glucocorticoids; Sarcoidosis

Indexed keywords

ALENDRONIC ACID; CORTICOSTEROID; ETIDRONIC ACID; PREDNISONE;

ABSORPTIOMETRY; ADULT; AGED; ARTICLE; BONE DENSITY; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SARCOIDOSIS;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; ALENDRONATE; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; BONE DENSITY; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PREDNISONE; SARCOIDOSIS; THORACIC DISEASES;

EID: 0030693626     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002239900352     Document Type: Article

References (32)

1. James DG, Jones Williams W (1985) Sarcoidosis and other granulomatous disorders. WB Saunders, Philadelphia, pp 134-141
2. Lukert BP, Raisz LG (1990) Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 112: 352-364
3. Silverman SL (1992) Management of corticosteroid-induced osteoporosis: a clinician's perspective. Calcif Tissue Int 50: 101-103
4. Dempster DW, Arlot MA, Meunier PJ (1983) Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int 35:410-417
5. Bressot C, Meunier PJ, Chapuy MC, Lejeune E, Edouard C, Darby AJ (1979) Histomorphometric profile, pathophysiology and reversibility corticosteroid-induced osteoporosis. Metab Bone Dis Rel 1:303-311
6. Gennari C, Scala C, Imbimbo B, Bernini M, Montagnani M, Nardi P, Fusi L, Avioli LV (1984) Acute changes in urinary radiocalcium following glucocorticoid administration in man. Adv Exp Med Biol 171:407-415
7. Nordin BEC, Marshall DH, Francis RM, Crilly RG (1981) The effect of sex steroid and corticosteroid hormone on bone. J Steroid Biochem 15:171-174
8. Suzuki Y, Ichikawa Y, Saito E, Homma M (1983) Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 32:151-156
9. Gennari C, Civitelli R (1986) Glucocorticoid-induced osteoporosis. Clin Rheum Dis 12:637-654
10. Lo Cascio V, Bonucci E, Imbimbo B, Ballanti P, Adami S, Milani S, Tartarotti D, Della Rocca C (1990) Bone loss in response to long-term glucocorticoid therapy. Bone Miner 8: 39-51
11. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J (1993) Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol and calcitonin. N Engl J Med 328:1747-1752
12. Eastell R (1995) Management of corticosteroid-induced osteoporosis. J Intern Med 237:439-447
13. Guaydier-Souquieres G, Kotzki PO, Sabatier JP, Basse-Cathalinat B, Loeb G (1996) In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study. Osteoporosis Int 6:171-177
14. Lukert BP, Johnson BE, Robinson RG (1992) Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 7:1063-1069
15. Montemurro L, Schiraldi G, Fraioli P, Tosi G, Riboldi A, Rizzato G (1991) Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcit Tissue Int 49:71-76
16. Healey JH, Paget SA, Williams-Russo P, Szatrowski TP, Schneider R, Spiera H, Mitnick H, Ales K, Schwartzberg P (1996) A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 58:73-80
17. Mulder H, Strays A (1994) Intermittent cyclical, etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 33:348-350
18. Diamond T, Mc Guigan L, Barbagallo S, Bryant C (1995) Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med 98:459-463
19. Struys A, Snelder AA, Mulder H (1995) Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 99:235-242
20. Reid IR, King AR, Alexander CJ, Ibbertson HK (1988) Prevention of steroid-induced osteoporosis with (3-amino-hydroxypropylidene)-1, disphosphonate (APD). Lancet i:143-146
21. Reid IR, Schooler BA, Stewart AW (1990) Prevention of glucocorticoid-induced osteoporosis. J Bone Miner Res 5:619-623
22. Gallagher SJ, Fenner JAK, Anderson K, Bryden FM, Bannam SW, Logue FC, Cowan RA, Boyle IT (1992) Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid-dependent lung disease: an open pilot study. Thorax 47:932-936
23. Lepore L, Pennesi M, Barbi E, Pozzi R (1991) Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clin Exp Rheumatol 9(6):33-35
24. Chesnut CH III, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Stock JL, Yood RA, Delmas PD, Kher U, Pryor-Tillotson S, Santora II AC (1995) Alendronate treament of postmenopausal osteoporotic women: effect of multiple dosages on bone mass and bone remodeling. Am J Med 99:144-152
25. Prockop DJ, Udenfriend S (1960) A specific method for the analysis of hydroxyproline in tissues and urine. Analytical biochemistry 1:228-239
26. Falcini F, Trapani S, Ermini M, Brandi ML (1996) Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling. Calcit Tissue Int 58:166-169
27. Montemurro L, Fraioli P, Rizzato G (1991) Bone loss in untreated longstanding sarcoidosis. Sarcoidosis 8:29-34
28. Rottoli P, Gonnelli S, Solitro S, Zacchei F, Fabbrini D, Gennari C, Vagliasindi M (1993) Alterations in calcium metabolism and bone mineral density in relation to the activity of sarcoidosis. Sarcoidosis 10:161-162
29. Nilas L, Nørgaard H, Pødenphant J, Gotfredsen A, Christiansen C (1987) Bone composition in the distal forearm. Scand J Clin Lab Invest 47:41-46.
30. WHO Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report no 843. World Health Organisation, Geneva, pp 1-129
31. Delmas PD (1993) Use of biochemical markers in assessing elucocorticoid impact on bone. In: Christiansen C, Riis B (eds) Osteoporosis 1993. Proc 4th Intal Symp on Osteoporosis. pp 516-518
32. Collin P, Nefussi JR, Wetterwald A, Nicolas V, Boy-Lefevre ML, Reish H, Forest N (1992) Expression of collagen, osteocalcin and bone alkaline phosphatase in mineralizing rat osteoblastic cell culture. Calcif Tissue Int 50:175-183